In vitro and in vivo evaluation of injectable implants for intratumoral delivery of 5-fluorouracil

References

• Spector T, Cao S, Rustum YM, et al. Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil. Cancer Res 1995;55:1239–41
   PubMed Web of Science ®Google Scholar
• Öman M, Blind PJ, Naredi P, et al. Treatment of non-resectable pancreatic cancer with intraperitoneal 5-FU and leucovorin IV. Eur J Surg Oncol 2001;27:477–81
   PubMedGoogle Scholar
• Kurokohchi K, Takaguchi K, Kita K, et al. Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-α. World J Gastroenterol 2005;11:5401–3
   PubMedGoogle Scholar
• Tanaka-Nozaki M, Tajiri T, Tanaka N, et al. Intratumoral induction of thymidylate synthase mRNA by 5-FU in colorectal cancer patients: association with survival. Oncol Rep 2003;10:1425–9
   PubMedGoogle Scholar
• Kim JH, Kim YS, Park K, et al. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release 2008;127:41–9
   PubMed Web of Science ®Google Scholar
• Sastre RL, Olmo R, Teijon C, et al. 5-Fluorouracil plasma levels and biodegradation of subcutaneously injected drug-loaded microspheres prepared by spray-drying poly(d,l-lactide) and poly(d,l-lactide-co-glycolide) polymers. Int J Pharm 2007;338:180–90
   PubMed Web of Science ®Google Scholar
• Liggins RT, D’amours S, Demetrick JS, et al. Paclitaxel loaded poly(l-lactic acid) microspheres for the prevention of intraperitoneal carcinomatosis after a surgical repair and tumor cell spill. Biomaterials 2000;21:1959–69
   PubMed Web of Science ®Google Scholar
• Blanco MD, Garcia O, Gomez C, et al. In-vivo drug delivery of 5-fluorouracil using poly(2-hydroxyethyl methacrylate-co-acrylamide) hydrogels. J Pharm Pharmacol 2000;52:1319–25
   PubMed Web of Science ®Google Scholar
• Lee JS, Chae GS, An TK, et al. Preparation of 5-fluorouracil-loaded poly(l-lactide-co-glycolide) wafer and evaluation of in vitro release behavior. Macromol Res 2003;11:183–8
   Web of Science ®Google Scholar
• Shikanov S, Shikanov A, Gofrit O, et al. Intratumoral delivery of paclitaxel for treatment of orthotopic prostate cancer. J Pharm Sci 2009;98:1005–14
   PubMedGoogle Scholar
• Jackson JK, Zhang X, Llewellen S, et al. The characterization of novel polymeric paste formulations for intratumoral delivery. Int J Pharm 2004;270:185–98
   PubMed Web of Science ®Google Scholar
• Jackson JK, Gleave ME, Yago V, et al. The suppression of human prostate tumor growth mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel. Cancer Res 2000;60:4146–51
   PubMed Web of Science ®Google Scholar
• Denkbas EB, Seyyal M, Piskin E. Implantable 5-fluorouracil loaded chitosan scaffolds prepared by wet spinning. J Memb Sci 2000;172:33–8
   Web of Science ®Google Scholar
• Gao H, Gu Y, Ping Q. The implantable 5-fluorouracil-loaded poly(l-lactic acid) fibers prepared by wet-spinning from suspension. J Control Release 2007;118:325–32
   PubMed Web of Science ®Google Scholar
• Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000;18:299–313
   PubMed Web of Science ®Google Scholar
• Lokich J. Infusional 5-FU: historical evolution, rationale, and clinical experience. Oncology 1998;12:19–22
   PubMed Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330–8
   PubMed Web of Science ®Google Scholar
• Sun H, Mei L, Song C, et al. The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials 2006;27:1735–40
   PubMed Web of Science ®Google Scholar
• Bourges JL, Bloquel C, Thomas A, et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 2006;58:1182–202
   PubMed Web of Science ®Google Scholar
• Sinha VR, Bansal K, Kaushik R, et al. Poly-ε-caprolactone microspheres and nanospheres: an overview. Int J Pharm 2004;278:1–23
   PubMed Web of Science ®Google Scholar
• Carcaboso AM, Chiappetta DA, Hocht C, et al. In vitro/in vivo characterization of melt-molded gabapentin-loaded poly(epsilon-caprolactone) implants for sustained release in animal studies. Eur J Pharm Biopharm 2008;70:666–73
   PubMedGoogle Scholar
• Altpeter H, Bevis MJ, Grijpma DW, Feijen J. Non-conventional injection molding of poly(lactide) and poly(epsilon-caprolactone) intended for orthopedic applications. J Mater Sci Mater Med 2004;15:175–84
   PubMed Web of Science ®Google Scholar
• Sprockel OL, Sen MH, Shivanand P, Prapaitrakul W. A melt-extrusion process for manufacturing matrix drug delivery systems. Int J Pharm 1997;155:191–9
   Web of Science ®Google Scholar
• Dordunoo SK, Oktaba AMC, Hunter W, et al. Release of taxol from poly(ε-caprolactone) pastes: effect of water-soluble additives. J Control Release 1997;44:87–94
   Web of Science ®Google Scholar
• Hou JW, Li CY, Cheng L, et al. Study on hydrophilic 5-fluorouracil release from hydrophobic poly (ε-caprolactone) cylindrical implants. Drug Dev Ind Pharm 2011;37:1068–75
   PubMed Web of Science ®Google Scholar
• Yoon JS, Jung HW, Kim MN, Park ES. Diffusion coefficient and equilibrium solubility of water molecules in biodegradable polymers. J Appl Polym Sci 2000;77:1716–22
   Web of Science ®Google Scholar
• Maring JG, Schouten L, Greijdanus B, et al. A simple and sensitive fully validated HPLC-UV method for the determination of 5-fluorouracil and its metabolite 5,6-dihydrofluorouracil in plasma. Ther Drug Monit 2005;27:25–30
   PubMedGoogle Scholar
• Zufia L, Aldaz A, Castellanos C, Giraldez J. Determination of 5-fluorouracil and its prodrug tegafur in plasma and tissue by high-performance liquid chromatography in a single injection: validation for application in clinical pharmacokinetic studies. Ther Drug Monit 2003;25:221–8
   PubMedGoogle Scholar
• Tamargo RJ, Myseros JS, Epstein JI, et al. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res 1993;53:329–33
   PubMed Web of Science ®Google Scholar
• Wang F, Blanco E, Ai H, et al. Modulating ε-lapachone release from polymer millirods through cyclodextrin complexation. J Pharm Sci 2006;95:2309–19
   PubMed Web of Science ®Google Scholar
• Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur J Pharm Biopharm 2001;54:107–17
   Google Scholar
• Wang S, Guo S, Cheng L. Disodium norcantharidate loaded poly(ε-caprolactone) microspheres. I. Preparation and evaluation. Int J Pharm 2008;350:130–7
   PubMed Web of Science ®Google Scholar
• Krishna Rao KSV, Chung I, Mallikarjuna Reddy K, Ha CS. PMMA-based microgels for controlled release of an anticancer drug. J Appl Polym Sci 2009;111:845–53
   Google Scholar
• Edlund U, Albertsson AC. Degradable polymer microspheres for controlled drug delivery. Adv Polym Sci 2002;157:67–112
   Web of Science ®Google Scholar
• Weinberg BD, Blanco E, Gao J. Polymer implants for intratumoral drug delivery and cancer therapy. J Pharm Sci 2008;97:1681–702
   PubMed Web of Science ®Google Scholar
• Fung LK, Saltzman WM. Polymeric implants for cancer chemotherapy. Adv Drug Deliv Rev 1997;26:209–30
   PubMed Web of Science ®Google Scholar
• Au JS, Jang SH, Zheng J, et al. Determinants of drug delivery and transport to solid tumors. J Control Release 2001;74:31–46
   PubMed Web of Science ®Google Scholar
• Evrard A, Cuq P, Robert B, et al. Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: in vitro and in vivo study. Int J Cancer 1999;80:465–70
   PubMedGoogle Scholar